Norinchukin Bank The Buys 10,055 Shares of Bristol-Myers Squibb (NYSE:BMY)

Norinchukin Bank The grew its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 11.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 95,991 shares of the biopharmaceutical company's stock after buying an additional 10,055 shares during the quarter. Norinchukin Bank The's holdings in Bristol-Myers Squibb were worth $5,429,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Bristol-Myers Squibb by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock valued at $10,743,262,000 after acquiring an additional 1,373,209 shares in the last quarter. Capital International Investors lifted its position in shares of Bristol-Myers Squibb by 7.5% in the 4th quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock worth $2,593,940,000 after buying an additional 3,218,865 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Bristol-Myers Squibb by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock valued at $2,505,967,000 after buying an additional 1,187,231 shares during the period. Norges Bank bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $1,989,525,000. Finally, Bank of New York Mellon Corp raised its stake in Bristol-Myers Squibb by 6.4% during the fourth quarter. Bank of New York Mellon Corp now owns 24,733,868 shares of the biopharmaceutical company's stock worth $1,398,948,000 after acquiring an additional 1,482,410 shares during the period. Institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Trading Down 2.7 %

Shares of NYSE:BMY traded down $1.29 during mid-day trading on Friday, hitting $47.40. The stock had a trading volume of 9,271,167 shares, compared to its average volume of 13,063,348. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market cap of $96.44 billion, a PE ratio of -10.75, a P/E/G ratio of 2.07 and a beta of 0.41. The company's 50 day moving average is $56.50 and its 200-day moving average is $56.50.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.25. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the prior year, the business earned ($4.40) EPS. On average, sell-side analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.23%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -56.11%.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of research reports. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Truist Financial upped their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. Citigroup increased their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb currently has an average rating of "Hold" and a consensus target price of $58.00.

Insider Activity

In other news, EVP Samit Hirawat bought 1,823 shares of the stock in a transaction on Friday, February 14th. The shares were purchased at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares of the company's stock, valued at $3,506,030.88. This trade represents a 2.94 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.